RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
18 nov. 2021 17h00 HE
|
RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
13 oct. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
03 déc. 2019 08h00 HE
|
Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
Eko Launches ‘Eko Home,' a Cardiac Remote Monitoring Application Enabling Powerful Drug-Data Combinations to Enhance Clinical Studies and Pharmaceutical Trials
25 juil. 2019 13h00 HE
|
Eko
San Francisco, July 25, 2019 (GLOBE NEWSWIRE) -- Eko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced Eko Home, a...
Endonovo Therapeutics Hires David Clark as Vice President of Sales
03 mai 2019 09h20 HE
|
Endonovo Therapeutics, Inc.
Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new...
Study Finds Variations in Percentage of Clinical Teams Using Simple and Complex Adaptive Trial Designs
04 sept. 2017 19h16 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - September 04, 2017) - Recent analysis of clinical development teams show that surveyed clinical teams are divided on whether or not companies should...
Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies
19 juil. 2017 19h23 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is...
Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams
22 juin 2017 15h41 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 22, 2017) - The majority of surveyed clinical trial teams -- from those with global responsibility to those positioned at the country level -- report...
Adaptive Design Trials Emerge As Most Popular Method Used By Pharma Companies to Reduce Phase 3 Failures
07 juin 2017 16h27 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - June 07, 2017) - About 60% of surveyed life science teams believe that using adaptive design trials in early-stage clinical studies increase the odds of...
Study Finds Variations in Percentage of Clinical Teams Using Adaptive Trials and When
11 mai 2017 20h00 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 11, 2017) - There is no one-size-fits-all approach to strategic adaptive trial design use, according a study published by business intelligence firm...